• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Apogee Therapeutics Inc.

    4/24/26 4:30:04 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APGE alert in real time by email
    DEFA14A 1 apge_defa_14a_2026.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

     

    Apogee Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

    img75088500_0.jpg

     


     

    APOGEE THERAPEUTICS, INC. 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM, MA 02453 V94486-P47026 You invested in APOGEE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 9, 2026. Get informed before you vote View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the proxy materials by requesting prior to May 26, 2026. If you would like to request a paper or email copy of the proxy materials or materials for future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. There is no charge to you for requesting a copy. Unless requested, you will not otherwise receive a paper or email copy. Your Vote Counts! APOGEE THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 8, 202611:59 PM ET For complete information and to vote, visit www.ProxyVote.comControl # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 9, 2026 11:00 AM, Eastern Time Virtually at: www.virtualshareholdermeeting.com/APGE2026 *The company will be hosting the meeting live via the Internet this year at the website address above. Please check the proxy materials for instructions on how to access the meeting.

     


     

    img75088500_1.jpg

     


     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet or by mail. You may view the proxy materials at www.proxyvote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters. Board Recommends Voting Items 1. Election of Class III Directors for terms expiring in 2029. For Nominees: 01) Mark C. McKenna 02) Jennifer Fox 03) William (BJ) Jones, Jr. 2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. For 3. Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement. For NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V94487-P47026

     


    Get the next $APGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGE

    DatePrice TargetRatingAnalyst
    5/1/2026$140.00Buy
    Rothschild & Co Redburn
    3/18/2026$83.00Hold
    Truist
    1/22/2026$83.00Outperform → Sector Perform
    RBC Capital Mkts
    1/7/2026Peer Perform
    Wolfe Research
    12/17/2025$95.00Overweight
    Stephens
    12/10/2025$103.00Buy
    Deutsche Bank
    11/3/2025$109.00Buy
    Craig Hallum
    10/21/2025$105.00Outperform
    Mizuho
    More analyst ratings

    $APGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apogee Therapeutics to Participate in Upcoming June Conferences

    SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentia

    5/28/26 4:01:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

    Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt  Combined with company's current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time SAN FRANCISCO and BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class pr

    5/27/26 6:31:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

    APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in-a-product potential for zumilokibart with asthma and eosinophilic esophagitis (EoE) trial plans shared today Management to host conference call today at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May

    5/27/26 6:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    12/16/24 6:00:10 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    SEC Filings

    View All

    Apogee Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

    5/27/26 6:40:32 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

    8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

    5/27/26 6:37:49 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Apogee Therapeutics Inc.

    144 - Apogee Therapeutics, Inc. (0001974640) (Subject)

    5/13/26 10:34:42 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $APGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Apogee Therapeutics with a new price target

    Rothschild & Co Redburn initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $140.00

    5/1/26 7:32:03 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Apogee Therapeutics with a new price target

    Truist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00

    3/18/26 8:22:50 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00

    1/22/26 8:24:52 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Henderson Michael Thomas sold $1,641,711 worth of shares (20,000 units at $82.09) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,115,987 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    5/15/26 8:00:12 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $462,784 worth of shares (5,500 units at $84.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.66% to 207,023 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    5/8/26 8:00:09 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Henderson Jane sold $164,080 worth of shares (2,000 units at $82.04) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 173,371 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    5/4/26 8:00:16 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Leadership Updates

    Live Leadership Updates

    View All

    Apogee Therapeutics Announces Agenda for Virtual R&D Day

    SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

    11/29/24 1:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

    SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

    11/18/24 7:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

    SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,

    9/9/24 7:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 5:46:11 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Apogee Therapeutics Inc.

    SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 11:16:12 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 10:18:32 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Financials

    Live finance-specific insights

    View All

    Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

    APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in-a-product potential for zumilokibart with asthma and eosinophilic esophagitis (EoE) trial plans shared today Management to host conference call today at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May

    5/27/26 6:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

    SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics' live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this l

    5/26/26 4:01:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

    APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients maintained vIGA 0/1Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart  Well tolerated across both dosing regimens, with safety profile generally in line with other agents in class APEX Part B 16-week induction expected to readout 2Q 2026, supporting expected initiation of Phase 3 zumilokibart trials in moderate-to-severe atopic dermatitis starting in 2H 2026 Dat

    3/23/26 6:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care